Loading…
← CockpitCompetitor Analysis › 600789.SS Shandong Lukang Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Shandong Lukang Pharmaceutical Co., Ltd. Class A600789.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shandong state-owned antibiotics and API manufacturer, a longtime major Chinese producer of bulk antibiotic drugs.

≈ A Chinese state-owned generic antibiotics makerMomentum strong 62
Mkt cap
$1.05B
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$19.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.4 pp
WACC 5.0%
Hurdle
-4 pp
Req g minus delivered
Close · CNYCN¥6.74
1D-0.9%
1W-4.5%
1M-10.7%
3M-12.1%
6M-18.4%
YTD-25.4%
1Y-33.5%
ATR %2.8%
52w lowhigh38.1% off high

What Shandong Lukang Pharmaceutical does

Shandong state-owned antibiotics and API manufacturer, a longtime major Chinese producer of bulk antibiotic drugs.

Sells antibiotic active ingredients in bulk to formulators in China and abroad at prices close to commodity levels, while its finished antibiotic drugs go to hospitals through distributors. Tighter rules on antibiotic use and plant emissions shape its results.

In one line: A Chinese state-owned generic antibiotics maker.

Products and services

  • Antibiotic APIs
  • Finished antibiotic formulations
  • Other generic drugs

Customers

  • Hospitals
  • Generic-drug formulators

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Antibiotics and APIs

What could go right

  • Antibiotic API export demand

What could go wrong

  • Overcapacity and price competition

Moat: none (scale). Legacy scale in commodity antibiotics without a differentiated product line.

Headquarters: Jining, Shandong, China · Employees: 6,469

Named competitors

Shandong Lukang Pharmaceutical at a glance

Size Shandong Lukang Pharmaceutical (600789.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 2080th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.74 on 18 Nov 2026.

Performance Over six months the shares fell 18.4%, against -8.7% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 6.5% over the last twelve months (peer median +3.1%); the operating margin is 2.8% (peer median 9.7%).

Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.1× (4th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points above its cost of capital (5.0% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 93600789.SS 81
Six months, rebased to 100: Shandong Lukang Pharmaceutical against the median of its 20 peers (local-currency closes).

Shandong Lukang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.74BCN¥5.74BCN¥6.18BCN¥6.12BCN¥5.60B
Revenue growth—-7%+1%+9%—
Gross profitCN¥1.48BCN¥1.14BCN¥1.34BCN¥1.40BCN¥1.15B
EBITDAn/aCN¥633MCN¥695MCN¥660MCN¥541M
Net incomeCN¥136MCN¥112MCN¥395MCN¥246MCN¥138M
Free cash flowCN¥161MCN¥359MCN¥124MCN¥266MCN¥16.0M
Capital expenditureCN¥366MCN¥339MCN¥279MCN¥338MCN¥428M
Total debtCN¥2.82BCN¥3.19BCN¥3.44BCN¥3.44BCN¥3.36B

Quarterly statements and history in the cockpit →

Shandong Lukang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%BLUEJETBSLN1952SVRA0027374553688513300497300702000650OMER6008124887MEDCLPYC688091605116688710VETO300119600789.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Lukang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×BLUEJETBSLN19520027374553300497300702000650600812MEDCL688091688710600789.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Lukang Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%BLUEJETBSLN0027374553688513300497300702000650600812605116688710VETO600789.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Lukang Pharmaceutical is the large dot.

Shandong Lukang Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600789.SS vs 600812.SS vs 000597.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Shandong Lukang Pharmaceutical 600789.SS$1.05B-18%-7%3%1.5×2.5%
North China Pharmaceutical 600812.SS$1.08B-12%-21%5%2.4×1.0%
Northeast Pharmaceutical 000597.SZ$895M-14%-6%3%0.9×-7.6%

How Shandong Lukang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Lukang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600789.SSPeer medianRank in peer set
1-month return-10.7%-4.7%7th lowest of 21
6-month return-18.4%-8.7%6th lowest of 21
Distance from 52-week high-38.1%-31.7%7th lowest of 21
Revenue growth (TTM)-6.5%+3.1%6th lowest of 18
Operating margin2.8%9.7%5th lowest of 19
EV / Sales1.5×3.1×4th cheapest of 19
Growth the price implies (Req g, 7 yrs)2.5%1.0%7th most demanding of 14
Growth delivered (Del g)+6.5%+7.7%7th lowest of 14
Hurdle (Req g minus delivered)-4.0 pp-3.6 pp7th least demanding of 14
ROIC minus cost of capital+0.4 pp-0.1 pp9th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%1.5×2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%8.1×40.8%+13.8%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%3.2×-5.6%+12.7%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%3.0×n/an/a
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%1.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%1.2×-0.3%+12.1%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%4.2×4.4%+7.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%4.0×7.5%-4.5%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%2.3×4.3%+3.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%0.9×-10.7%-7.0%
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%2.4×1.0%-4.2%
SAWAI 4887.TJapan$1.01B-18%+2%9%1.3×n/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%49.6×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%19.3×n/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%4.2×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%5.2×12.7%+19.4%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%1.5×-3.6%+4.2%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%2.3×4.9%+11.3%

Questions

Who are Shandong Lukang Pharmaceutical's main competitors?
Named competitors: North China Pharmaceutical (600812.SS), Northeast Pharmaceutical Group (000597.SZ). The cockpit's measured peer set (industry) also includes Blue Jet Healthcare (BLUEJET.NS), Basilea Pharmaceutica (BSLN.SW), Everest Medicines (1952.HK), Savara (SVRA), Sunflower Pharmaceutical (002737.SZ), Towa Pharmaceutical (4553.T).
Is Shandong Lukang Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.5× against a peer median of 3.1×, 4th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Shandong Lukang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -18.4% against -8.7% for the median peer; over one year -33.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.